According to a report,“Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 – 2025”, published by Grand View Research, Inc., The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025. The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.
Key Takeaways from the report:
-
Diabetes segment led the market in 2017, in terms of revenue generation,owing to higher prevalence and drug usage
-
Obesity segment is expected to register a CAGR of 9.27% over the forecast period owing to increasing prevalence as a result of sedentary lifestyle changes
-
Drug therapy was the most-preferred therapy due to its high reliability proven success and availability of various types of drugs to treat metabolic diseases
-
The segment is expected to maintain its dominance even during the forecast years due to the introduction of smart technology to deliver antidiabetic drug on a regulated basis
-
Key companies in this market are Novo Nordisk A/S;Sanofi S.A.; BoehringerIngelheim GmbH; Eli Lilly and Company; Merck KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC; AbbVie, Inc.;Biocon Ltd.;BioMarinPharmaceutical, Inc.; Bristol-Myers Squibb Company; Cipla, Inc.; and CymaBay Therapeutics, Inc.
-
Most of these companies are focusing on strategies, such as collaborations, expansion of product portfolios, and M&A to maintain their industry position
-
Oral route of administration was the key revenue-generating segment in 2017owing to its benefits, such as high reliability and ease of administration
-
North America was the largest regional market in 2017 and will maintain the trend in future due to the presence of key companies and rising cases of diabetes and obesity
Browse More Reports in Pharmaceuticals:
• Erectile Dysfunction Drugs Market: Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this erectile dysfunction drugs market.
• Osteoporosis Drugs Market: An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.
Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.
Grand View Research has segmented the global metabolic disorder therapeutics market on the basis of disease, therapy type, route of administration, and region:
Metabolic Disorder Therapeutics Disease Outlook (Revenue, USD Billion, 2014 – 2025)
-
Lysosomal Storage Diseases
-
Gaucher’s Disease
-
Metachromatic Leukodystrophy
-
Hurler – Scheie
-
Sanfilipo A
-
Others
-
-
Diabetes
-
Obesity
-
Inherited Metabolic Disorders
-
Hypercholesterolemia
Metabolic Disorder Therapy Type Outlook (Revenue, USD Billion, 2014 – 2025)
-
Enzyme Replacement Therapy
-
Cellular Transplantation
-
Small Molecule Based Therapy
-
Substrate Reduction Therapy
-
Gene Therapy
-
Drug Therapy
Metabolic Disorder Therapeutics Route of Administration Outlook (Revenue, USD Billion, 2014 – 2025)
-
Oral
-
Parenteral
-
Others
Metabolic Disorder Therapeutics Regional Outlook (Revenue, USD Billion, 2014 – 2025)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
Germany
-
U.K.
-
-
Asia Pacific
-
Japan
-
China
-
-
Latin America
-
Brazil
-
-
Middle East & Africa
-
South Africa
Explore metabolic disorder therapeutics market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: Switzerland
Website: www.grandviewresearch.com/industry-analysis/metabolic-disorder-therapeutics-market